The Renocrit Injection is formulated with Recombinant Human Erythropoietin Alfa which serves as an erythropoiesisstimulating agent Its primary purpose is to address anemia resulting from cancer chemotherapy treatment and the use of medications for HIV treatment The mechanism of action of Recombinant Human Erythropoietin Alfa entails stimulating the bone marrow the soft tissue located inside the bones responsible for red blood cell production to generate a higher quantity of red blood cells It is crucial to inform your doctor about any medications you are currently taking or have taken in the past before starting this treatment